Core Viewpoint - Elanco Animal Health reported quarterly earnings of 0.14pershare,missingtheZacksConsensusEstimateof0.15 per share, but showing an improvement from 0.08pershareayearago,indicatinga−6.671.02 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.83%, although this represents a decline from year-ago revenues of 1.04billion[2]−Overthelastfourquarters,ElancohassurpassedconsensusEPSestimatesthreetimesandtoppedconsensusrevenueestimatesthreetimesaswell[2]StockPerformance−Elancoshareshavedeclinedapproximately8.30.31 on revenues of 1.2billion,andforthecurrentfiscalyear,itis0.89 on revenues of $4.51 billion [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which Elanco belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8]